OnKure Therapeutics, Inc.

OKUR Nasdaq SEC CIK 1637715
Follow OnKure Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$17.8M −21.4% vs same quarter last year
EPS, diluted −$0.36 +67% vs same quarter last year
Operating cash flow −$13.1M −0.3% vs same quarter last year
Operating income −$19.4M −24.8% vs same quarter last year
Net income by quarter
−$17.4M
−$15.9M
−$15.4M
−$14.7M
−$13.5M
−$15.2M
−$15.3M
−$17.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$59.5M
FY24−$52.7M
FY23−$35.3M
FY22−$52M
FY21−$39.8M
FY20−$19.5M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$51.9M
FY24−$51.2M
FY23−$34.8M
FY22−$47.7M
FY21−$38.2M
FY20−$18.6M
FY19-